We noticed JavaScript is turned off in your browser settings. For a better viewing experience, enable JavaScript. If you're unsure of how to do this, click here to download a new browser.

FOR PREVIEW ONLY (Print)

Alexander Ljubimov, PhD

Director, Eye Program Board of Governors Regenerative Medicine Institute

Professor, Biomedical Sciences

Professor, Neurosurgery

Email:

ljubimov@cshs.org

Research Office:

Phone:

310-248-8583

Fax:

310-248-8066

Alexander Ljubimov, PhD

Director, Eye Program Board of Governors Regenerative Medicine Institute

Professor, Biomedical Sciences

Professor, Neurosurgery

Alexander Ljubimov, PhD, focuses his research on gene therapy for diabetic corneal stem cells, generation of corneal epithelium from iPSC for limbal stem cell deficiency therapy, inhibition of protein kinase CK2 to block pathological retinal angiogenesis and tumor growth, miRNA in normal and diabetic cornea, and targeted nanodrugs for cancer.

View NIH Biographical Sketch as a PDF

  • Master's: Moscow State University, 1974
  • Doctorate: N.N. Blokhin Russian Cancer Research Center, 1979

View CV as a PDF

  • American Diabetes Association, Current
  • Association for Research in Vision and Ophthalmology, Current
  • Editorial Board Member: Experimental Biology and Medicine, Current
  • Editorial Board Member: Investigative Ophthalmology and Visual Science, Current
  • Editorial Board Member: Molecular Vision, Current
  • Editorial Board Member: PLoS One, Current
  • Executive Editor: Experimental Eye Research, Current
  • Royal Society of Medicine (London), Current
  • Gold Fellow, Association for Research in Vision and Ophthalmology, 2014
  • International Society for Eye Research, current
  • Eleanor Roosevelt International UICC Fellowship, American Cancer Society, 1991-92

Show moreShow less

Click here for a list of peer-reviewed publications.

  • Patil R, Ljubimov AV, Gangalum PR, Ding H, Portilla-Arias J, Wagner S, Inoue S, Konda B, Rekechenetskiy A, Chesnokova A, et al. MRI virtual biopsy and treatment of brain metastatic tumors with targeted nanobioconjugates: nanoclinic in the brain. ACS Nano. 2015;9(5):5594-5608.
  • Sareen D, Saghizadeh M, Ornelas L, Winkler MA, Narwani K, Sahabian A, Funari VA, Tang J, Spurka L, Punj V, Maguen E, Rabinowitz YS, Svendsen CN, Ljubimov AV. Differentiation of human limbal-derived induced pluripotent stem cells into limbal-like epithelium. Stem Cells Transl Med. 2014;3(9):1002-1012.
  • Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, Schwartz M, Farkas DL. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage. 2011;54 Suppl 1:S204-217.
  • Kramerov AA, Ahmed K, Ljubimov AV. Cell rounding in cultured human astrocytes and vascular endothelial cells upon inhibition of CK2 is mediated by actomyosin cytoskeleton alterations. J Cell Biochem. 2012;113: 2948-2956.
  • Saghizadeh M, Dib CM, Brunken WJ, Ljubimov AV. Normalization of wound healing and stem cell marker patterns in organ-cultured human diabetic corneas by gene therapy of limbal cells. Exp Eye Res. 2014;129:66-73.
  • Saghizadeh M, Soleymani S, Harounian A, Bhakta B, Troyanovsky SM, Brunken WJ, Pellegrini G, Ljubimov AV. Alterations of epithelial stem cell marker patterns in human diabetic corneas and effects of c-met gene therapy. Mol Vis. 2011;17:2177-2190.
  • Ding H, Inoue S, Ljubimov AV, Patil R, Portilla-Arias J, Hu J, Konda B, Wawrowsky KA, Fujita M, Karabalin N, et al. Inhibition of brain tumor growth by intravenous poly(β-L-malic acid) nanobioconjugate with pH-dependent drug release. Proc Natl Acad Sci U.S.A. 2010;107(42):18143-18148.

Show moreShow less